Goldman Sachs’s Entera Bio ENTX Stock Holding History

Goldman Sachs’s Portfolio ENTX Stock Details ENTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-12,327	Closed	-$23.9K	–	6628
2025 Q4	$23.9K	Buy	+12,327	New	+$28.9K	﹤0.01%	6332

Other funds holding ENTX

KCM

Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

PHP

Parkman Healthcare Partners Stamford, Connecticut $970M AUM 79.46% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

SFCM

Seven Fleet Capital Management Mountain View, California $318M AUM

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return

SSA

Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return

SEIA

Signature Estate & Investment Advisors Los Angeles, California $5.56B AUM 26.66% 1-Year Est. Return

Goldman Sachs's ENTX Position: Q1 2026 in Review

Goldman Sachs sold out of Entera Bio (ENTX) in Q1 2026, closing a stake of 12,327 shares — an estimated $23.9K sold.

Goldman Sachs first reported a position in ENTX in Q4 2025 and held it in 1 quarter. The position peaked at $23.9K in Q4 2025. 26 funds tracked by Wall St. Rank hold ENTX as of Q1 2026.

Goldman Sachs reported no remaining Entera Bio position as of Q1 2026 after selling out during the quarter.
Goldman Sachs sold 12,327 Entera Bio shares in Q1 2026, an estimated $23.9K.
Goldman Sachs first reported a position in Entera Bio in Q4 2025 and held it in 1 quarter.
Goldman Sachs's Entera Bio position peaked at $23.9K in Q4 2025.
26 funds tracked by Wall St. Rank held Entera Bio as of Q1 2026.

Based on Goldman Sachs's 13F filing for Q1 2026, filed 15 May 2026.